Vasculoprotective Effects of Vildagliptin. Focus on Atherogenesis

Vildagliptin is a representative of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, antihyperglycemic drugs, approved for use as monotherapy and combination therapy in type 2 diabetes mellitus. By inhibiting enzymatic decomposition, DPP-4 inhibitors increase the half-life of incretins such as GLP-1 (Gluc...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Michał Wiciński, Karol Górski, Eryk Wódkiewicz, Maciej Walczak, Magdalena Nowaczewska, Bartosz Malinowski
Format: Artigo
Jezik:Inglês
Izdano: MDPI AG 2020-03-01
Serija:International Journal of Molecular Sciences
Teme:
vildagliptin
endothelium
inflammation
atherogenesis
pathways
pharmacology
Online dostop:https://www.mdpi.com/1422-0067/21/7/2275
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki